Qihan Biotech presented an oral and several poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting.

At the upcoming 2025 ASH Annual Meeting, Qihan Biotech will present new data highlighting significant progress across its off-the-shelf and in vivo CAR-T cell therapy programs.

The U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QT-019B.